Minoxidil and wound contraction.
Minoxidil has been proposed as a potential topical inhibitor of wound contraction and proliferative scarring. Suggestions for this application are derived from in vitro investigations demonstrating inhibition of various fibroblastic functions. The purpose of this study was to attempt to establish in vivo support of these effects using an established animal model of wound contraction. Standardized cutaneous wounds were created on the dorsum of Sprague-Dawley rats, which were divided equally into six treatment groups. Wounds were treated daily after tracing their unhealed areas. On complete closure of the wounds, analyses of the contraction rates and tensile strength were performed for comparison among groups. Minoxidil did not demonstrate significant inhibition of wound contraction rates relative to either an inert vehicle, an active vehicle, or no treatment. Contrarily, as previously demonstrated in this animal model, silver sulfadiazine did demonstrate significant inhibition of wound contraction rates relative to both vehicles. No significant difference in tensile strength was demonstrated among groups. These observations do not support the proposed use of minoxidil as an "antifibrotic" agent.
Polo
M
M
University of South Florida, Division of Plastic Surgery, USA.
Hill
D P
DP
Carney
G
G
Ko
F
F
Wright
T E
TE
Robson
M C
MC
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000494:pharmacology; D008914:Minoxidil / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012837:Silver Sulfadiazine / Q000494:pharmacology; D013718:Tensile Strength; D014665:Vasodilator Agents / Q000494:pharmacology*; D014945:Wound Healing / Q000502:physiology*
D000891:Anti-Infective Agents, Local; D014665:Vasodilator Agents; D008914:Minoxidil; D012837:Silver Sulfadiazine